(Total Views: 201)
Posted On: 08/22/2023 6:07:48 PM
Post# of 63
Matinas deserves congratulations for getting publication of the ENACT trial results in a peer reviewed journal.
Unfortunately, the position taken by the FDA regarding a Phase 3 trial for MAT 2203 for invasive fungal infections has made to impractical for Matinas to conduct such a study.
In light of this setback, I think it would make sense for Matinas to go back to the original plan—a Phase 3 pivotal trial for CM.
Approval for this indication would validate MAT 2203 as a viable drug, and Matinas as a promising company, and could garner interest from potential partners.
While sales for CM would likely be modest, MAT 2203 could possibly be used off label for other indications that would help to validate the use of MAT 2203 for other IFI (along with the LPAD pathway).
Matinas sorely needs a “W,” and getting approval of MAT 2203 for some indication could be the win it needs to get positive recognition and possible funding.
LM
Unfortunately, the position taken by the FDA regarding a Phase 3 trial for MAT 2203 for invasive fungal infections has made to impractical for Matinas to conduct such a study.
In light of this setback, I think it would make sense for Matinas to go back to the original plan—a Phase 3 pivotal trial for CM.
Approval for this indication would validate MAT 2203 as a viable drug, and Matinas as a promising company, and could garner interest from potential partners.
While sales for CM would likely be modest, MAT 2203 could possibly be used off label for other indications that would help to validate the use of MAT 2203 for other IFI (along with the LPAD pathway).
Matinas sorely needs a “W,” and getting approval of MAT 2203 for some indication could be the win it needs to get positive recognition and possible funding.
LM
(1)
(0)
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]
Scroll down for more posts ▼
